Published in Vaccine Weekly, April 13th, 2005
Chromos will issue shares, warrants, and/or convertible notes to acquire all outstanding shares of Anosys.
Completion of the acquisition is subject to satisfactory due diligence, execution of definitive agreements, and approval by Anosys' shareholders and regulatory authorities.
"The acquisition of Anosys will provide a cash infusion, extend our operating runway, and expand our shareholder base," said Alistair Duncan, president and CEO of Chromos. "The transaction will also enhance our partnering opportunities, in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.